摘要 |
<p>PCT No. PCT/GB95/02231 Sec. 371 Date Apr. 2, 1997 Sec. 102(e) Date Apr. 2, 1997 PCT Filed Sep. 21, 1995 PCT Pub. No. WO96/10421 PCT Pub. Date Apr. 11, 1996The invention relates to a vaccine composition adapted for mucosal administration, and in particular for intranasal administration, the composition comprising an influenza virus antigen or antigens, such as haemagglutinin and neuraminidase influenza virus antigens, and an effective adjuvant amount of a chitosan. The compositions can be used to immunise a host against infection with influenza, the chitosan serving to enhance the stimulation of a protective IgA mucosal immune response and an IgG systemic immune response.</p> |